Abstract N6-methyladenosine (m6A) is the most prevalent and well-characterized internal
chemical modification in eukaryotic RNA, influencing gene expression and phenotypic …

Background The molecular mechanisms driving hepatocellular carcinoma (HCC) remain
largely unclear. As one of the major epitranscriptomic modifications, N 6-methyladenosine …

RNA modification is considered as an epigenetic modification that plays an indispensable
role in biological processes such as gene expression and genome editing without altering …

Background A number of studies have demonstrated that N6‐methyladenosine (m6A) plays
a vital role in the pathological process of various tumours. Recently, it was found that m6A …

Simple Summary Despite major recent therapeutic advances, melanoma remains the
deadliest form of skin cancer due to the capacity of melanoma cells to adapt to drug …

Hypoxic microenvironment is clinically associated with metastasis and poor prognosis of
numerous cancers. The mechanisms by which intratumoral hypoxia regulates metastasis …

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) is an emerging prognostic
indicator, and its elevated expression correlates with malignancy in a broad spectrum of …

N6‐Methyladenosine (m6A) is the most common mRNA modification in eukaryotes and is a
dynamically reversible posttranscriptional modification. The enzymes involved in m6A …

METTL16, a human m6A RNA methyltransferase, is currently known for its modification of
U6 and MAT2A RNAs. Several studies have identified additional RNAs to which METTL16 …

Background: The immune checkpoint inhibitors (ICIs) has dramatically changed the
therapeutic area of cancers. A great number of patients with CRC exhibit poor response rate …